Carmell (CTCX) & The Competition Financial Survey

Risk and Volatility

Carmell has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Comparatively, Carmell’s competitors have a beta of 3.80, suggesting that their average stock price is 280% more volatile than the S&P 500.

Valuation and Earnings

This table compares Carmell and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Carmell	$32,839.00	-$15.44 million	-1.28
Carmell Competitors	$170.32 million	-$17.87 million	-11.76

Carmell’s competitors have higher revenue, but lower earnings than Carmell. Carmell is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Institutional & Insider Ownership

24.2% of Carmell shares are held by institutional investors. Comparatively, 40.1% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 29.0% of Carmell shares are held by insiders. Comparatively, 14.1% of shares of all “Surgical & medical instruments” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Carmell and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Carmell	N/A	-217.50%	-50.22%
Carmell Competitors	-1,253.12%	-231.08%	-33.37%

Summary

Carmell beats its competitors on 5 of the 9 factors compared.

About Carmell

Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.